Funding and management of intermediate and applied biotechnology research and development projects.
|Head Office||North Ryde NSW|
|Registry||Computershare Investor Services|
|Chair Person||Michael Hoy|
|GICS Industry||Pharmaceuticals, Biotechnology & Life Sciences|
|Market Cap||$24 m|
|Shares on Issue||901 m|
|52 Week H/L|
Directors and Management
Mr Michael J Hoy
Non-Executive Director,Non-Executive Chairman 07/02/2000
Mr Hoy has more than 30 years corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.
Mr Robert Bain Thomas
Non-Executive Director 07/03/2012
Mr Thomas has over 35 years experience in the securities industry, with Potter Partners (now UBS), County NatWest and Citigroup. He is the chairman of Starpharma Holdings Limited. He is a director of Aus Bio Limited and REVA Medical Limited and a former director of Virgin Australia Limited. He chairs Grahger Retail Securities Pty Ltd and a director of O'Connell Street Associates Pty Limited. Mr Thomas has a Bachelor of Economics degree from Monash University (1963 - 1966). He is a Master Stockbroker.
BEc, MSDIA, SF Fin, FFINSIA, FAICD, MSAA,AM,FRSN,A Male
Dr Michelle Miller
Managing Director 21/06/2002
Dr Miller has worked for over 25 years in the bioscience industry, with experience in commercial drug development. Her experience includes several years at Johnson and Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.
BSc, MSc, PhD, GCertAppFin (Finsia) Female
Dr Susan Margaret Pond
Non-Executive Director 07/03/2012
Dr Pond has a scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, most recently as chairman and managing director of Johnson and Johnson Research Pty Limited (2003-2009). Her previous non-executive positions include chair of AusBiotech Limited and director of Australian Nuclear Science and Technology Organisation, Wound Management Innovation CRC and Australian Academy of Technological Sciences and Engineering (ATSE). Dr Pond also served as a board member of Commercialisation Australia and Innovation Australia. Dr Pond is currently chair of the New South Wales Smart Sensing Network and director of the Trusted Autonomous Systems Defence Cooperative Research Centre, Vectus Biosystems Ltd and Australian Phenomics Network.
AM, MD, DSc, FTSE, FAICD, FAAHMS, MBBS,FATSE, Female
Professor Stephen Alister Locarnini
Non-Executive Director 23/10/2018
Professor Locarnini is a past director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D for the Western Pacific Region (WPRO). He is a inventor on over 20 internationally granted patents. He worked at the Victorian Infectious Diseases Reference Laboratory from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL. He subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998. He is the recipient of numerous awards including the European Association for the Study of Liver Disease (EASL) International Recognition Award in 2010, the Malaysian Liver Foundation's Medal for work on Viral Hepatitis in 2003 and the Gastroenterological Society of Australia (GESA) Distinguished Research Prize in 2013. In 2019 he received the William H. Prusoff HEP DART Lifetime Achievement Award. He is author of 289 peer-reviewed articles, 24 invited editorials and 100 book chapters and reviews and every year delivers numerous invited, and reviews and every year delivers numerous invited, plenary, and named lectures at major international meetings and conferences. He currently has an academic appointment at the University of Melbourne. He is a member of the Scientific Advisory Board of a number of emerging as well as established pharmaceutical and biotechnology companies. In 2017, he co-founded the biotech start-up company CLEAR-B with the Morningside-Newton Investment group in Boston, USA. He is also the Hepatitis Virus Editor for Antiviral Therapy.
BSc(Hons), PhD, MBBS, FRC(Path) Male
Top 20 Shareholders
|1.||Jey Investment Pty Ltd||14,440,945||2.06|
|2.||Dr Angela Fay Dulhunty||10,000,000||1.42|
|3.||Umbiram Pty Ltd (Michael Hoy Super Fund A/C)||9,347,793||1.33|
|4.||Armco Barriers Pty Ltd||7,800,000||1.11|
|5.||Dns Accounting And Law Consultancy Pty Ltd||7,753,488||1.10|
|6.||Citicorp Nominees Pty Limited||7,495,962||1.07|
|7.||Fordholm Investments Pty Ltd (Fordholm Super Fund A/C)||7,000,000||1.00|
|8.||Rookharp Capital Pty Limited||7,000,000||1.00|
|9.||Pathold No 222 Pty Ltd||5,200,000||0.74|
|10.||Scott'S A V Pty Ltd (Scotts Acorn Emp S/F A/C)||4,918,000||0.70|
|11.||Edstop Pty Limited (Superannuation Fund A/C)||4,071,588||0.58|
|12.||Road & Construction Supplies Of Australia Pty Ltd (Keller Super Fund A/C)||3,800,000||0.54|
|13.||Mr Robert Thomas And Mrs Kyrenia Thomas (Rob Thomas Super Fund A/C)||3,663,195||0.52|
|14.||Dr Sanjiv Pathak||3,632,313||0.52|
|15.||Attollo Copia Pty Ltd (F A Pires Super Fund A/C)||3,600,565||0.51|
|16.||Mr Peter James Nightingale||3,594,903||0.51|
|17.||Mr Mark Andrew Peterson||3,300,000||0.47|
|18.||Mr John Yan||3,266,858||0.47|
|19.||Mr William John Dunn||3,200,000||0.46|
|20.||Mr Charles Tollios Panos||3,099,234||0.44|